Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Evolus fundamentals unchanged despite ITC delay, says Mizuho » 12:45
06/02/20
06/02
12:45
06/02/20
12:45
EOLS

Evolus

$4.88 /

-0.275 (-5.33%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan says Evolus (EOLS) shares are facing pressure today after it was announced the target date for an initial determination in the ongoing International Trade Commission case between Medytox/Allergan and Daewoong/Evolus has been pushed out one month from June 5 to July 6. It appears the delay is due to Daewoong recently submitting four additional documents for review, as well as challenges the judge and his staff are facing due to working remotely, Divan tells investors in a research note. The analyst, however, continues to expect Daewoong/Evolus to prevail in the case, or for Daewoong to pay a royalty as part of a settlement. Divan expects continued volatility in Evolus shares until the initial determination is made public but feels the company's fundamentals are unchanged. The analyst keeps a Buy rating on Evolus with an $8 price target.

ShowHide Related Items >><<
EOLS Evolus
$4.88 /

-0.275 (-5.33%)

EOLS Evolus
$4.88 /

-0.275 (-5.33%)

05/26/20 Mizuho
Evolus rally Friday has no clear explanation, says Mizuho
05/22/20 Barclays
News from Korea on Medytox has 'no implications' for Evolus, says Barclays
05/22/20 Cantor Fitzgerald
Evolus stock move likely good news, says Cantor Fitzgerald
05/13/20 Barclays
Evolus price target lowered to $4 from $9 at Barclays
EOLS Evolus
$4.88 /

-0.275 (-5.33%)

Hot Stocks
Evolus falls after ITC extends determination target date by one month » 12:41
06/02/20
06/02
12:41
06/02/20
12:41
EOLS

Evolus

$4.94 /

-0.22 (-4.27%)

Evolus disclosed earlier…

Evolus disclosed earlier today that the administrate law judge assigned to the International Trade Commission action issued a decision extending the target date for an initial determination from June 5 to July 6. The decision also extended the target date for the final determination by the ITC from October 6 to November 6. The administrative law judge's decision regarding the extension of the target dates will become the decision of the ITC unless a party to the ITC action files a petition for review of the administrative law judge's decision, the company added. Evolus is a party to an ITC case which is entitled "In the Matter of Certain Botulinum Toxin Products." Shares of Evolus are down 4% to $4.92 in midday trading.

ShowHide Related Items >><<
EOLS Evolus
$4.94 /

-0.22 (-4.27%)

EOLS Evolus
$4.94 /

-0.22 (-4.27%)

05/26/20 Mizuho
Evolus rally Friday has no clear explanation, says Mizuho
05/22/20 Barclays
News from Korea on Medytox has 'no implications' for Evolus, says Barclays
05/22/20 Cantor Fitzgerald
Evolus stock move likely good news, says Cantor Fitzgerald
05/13/20 Barclays
Evolus price target lowered to $4 from $9 at Barclays
EOLS Evolus
$4.94 /

-0.22 (-4.27%)

Over a week ago
Recommendations
Evolus rally Friday has no clear explanation, says Mizuho » 06:55
05/26/20
05/26
06:55
05/26/20
06:55
EOLS

Evolus

$4.46 /

+0.37 (+9.05%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan sees no clear explanation for the jump in Evolus shares on Friday. The analyst maintains a Buy rating on the name with an $8 price target. A rally on the Korean Ministry of Food and Drug Safety's recent order for Medytox to provisionally cease manufacturing and marketing of Medytoxin products does not make sense, Divan tells investors in a research note. If anything, the news is a positive for Medytox and could be viewed as a negative for Evolus, says the analyst. Divan thinks there could some short covering ahead of the International Trade Commission. One of the main overhangs on Evolus shares this year has been the ongoing ITC hearing between Medytox and Daewoong and implications that the decision may have on Evolus' ability to commercialize Jeuveau in the U.S, says Divan. A preliminary decision from the ITC is expected by June 5, with a final decision expected in October, he notes.

ShowHide Related Items >><<
EOLS Evolus
$4.46 /

+0.37 (+9.05%)

EOLS Evolus
$4.46 /

+0.37 (+9.05%)

05/22/20 Barclays
News from Korea on Medytox has 'no implications' for Evolus, says Barclays
05/22/20 Cantor Fitzgerald
Evolus stock move likely good news, says Cantor Fitzgerald
05/13/20 Barclays
Evolus price target lowered to $4 from $9 at Barclays
05/12/20 SunTrust
Evolus price target lowered to $12 from $18 at SunTrust
EOLS Evolus
$4.46 /

+0.37 (+9.05%)

Recommendations
News from Korea on Medytox has 'no implications' for Evolus, says Barclays » 12:45
05/22/20
05/22
12:45
05/22/20
12:45
EOLS

Evolus

$4.90 /

+0.81 (+19.80%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad attributed this morning's surge in shares of Evolus to a Korean Times report that Medytox has received a court order allowing the company to resume sales of Meditoxin, which had been suspended since April 17. This would have provided some upside to local players like Hugel or Daewoong, but is solely applicable to the Korean market, where Evolus "is not a market participant," Prasad tells investors. The latest developments in Korea "are in no way related to the ITC complaint" involving the company, added Prasad, who believes there has been "a mispriced reaction by the market, likely assuming any legal news to be an update on the much awaited ITC litigation update." Prasad maintains an Underweight rating and $4 price target on Evolus shares.

ShowHide Related Items >><<
EOLS Evolus
$4.90 /

+0.81 (+19.80%)

EOLS Evolus
$4.90 /

+0.81 (+19.80%)

05/22/20 Cantor Fitzgerald
Evolus stock move likely good news, says Cantor Fitzgerald
05/13/20 Barclays
Evolus price target lowered to $4 from $9 at Barclays
05/12/20 SunTrust
Evolus price target lowered to $12 from $18 at SunTrust
05/12/20 Mizuho
Evolus price target lowered to $8 from $10 at Mizuho
EOLS Evolus
$4.90 /

+0.81 (+19.80%)

Recommendations
Evolus stock move likely good news, says Cantor Fitzgerald » 11:25
05/22/20
05/22
11:25
05/22/20
11:25
EOLS

Evolus

$5.67 /

+1.58 (+38.63%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Evolus shares, saying there is likely good news driving the stock 40%-50% higher, though the company is not currently available for comment. Evolus confirmed there is no ITC preliminary decision yet, she says, but adds that since Medytox shares are also higher, it could mean that there has been a settlement between the companies, removing a significant overhang on Evolus shares.

ShowHide Related Items >><<
EOLS Evolus
$5.67 /

+1.58 (+38.63%)

EOLS Evolus
$5.67 /

+1.58 (+38.63%)

05/13/20 Barclays
Evolus price target lowered to $4 from $9 at Barclays
05/12/20 SunTrust
Evolus price target lowered to $12 from $18 at SunTrust
05/12/20 Mizuho
Evolus price target lowered to $8 from $10 at Mizuho
04/17/20 Mizuho
Evolus price target lowered to $10 from $12 at Mizuho
EOLS Evolus
$5.67 /

+1.58 (+38.63%)

Recommendations
Evolus price target lowered to $4 from $9 at Barclays » 06:36
05/13/20
05/13
06:36
05/13/20
06:36
EOLS

Evolus

$4.33 /

-0.03 (-0.69%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad lowered the firm's price target on Evolus to $4 from $9 and keeps an Underweight rating on the shares. The analyst's channel work shows that while Q3 may see strong pent-up demand, processing bandwidth with aestheticians will be the key bottleneck in meeting demand. Prasad sees multiple uncertainties of post COVID demand and ongoing litigation risks for Evolus.

ShowHide Related Items >><<
EOLS Evolus
$4.33 /

-0.03 (-0.69%)

EOLS Evolus
$4.33 /

-0.03 (-0.69%)

05/12/20 SunTrust
Evolus price target lowered to $12 from $18 at SunTrust
05/12/20 Mizuho
Evolus price target lowered to $8 from $10 at Mizuho
04/17/20 Mizuho
Evolus price target lowered to $10 from $12 at Mizuho
03/27/20 H.C. Wainwright
Evolus price target lowered to $16 from $31 at H.C. Wainwright
EOLS Evolus
$4.33 /

-0.03 (-0.69%)

Recommendations
Evolus price target lowered to $12 from $18 at SunTrust » 08:31
05/12/20
05/12
08:31
05/12/20
08:31
EOLS

Evolus

$4.36 /

+0.22 (+5.31%)

SunTrust analyst Gregg…

SunTrust analyst Gregg Gilbert lowered the firm's price target on Evolus to $12 from $18 after its Q1 results. The analyst is citing lower Jeuveau sales in the quarter, driven by COVID-19 headwinds in the near term and as well as recessionary pressures over the medium term. Gilbert still keeps a Buy rating on the shares however and expects Jeuveau demand to rebound, maintaining that Evolus can capture a material portion of the botulinum toxin market over time.

ShowHide Related Items >><<
EOLS Evolus
$4.36 /

+0.22 (+5.31%)

EOLS Evolus
$4.36 /

+0.22 (+5.31%)

05/12/20 Mizuho
Evolus price target lowered to $8 from $10 at Mizuho
04/17/20 Mizuho
Evolus price target lowered to $10 from $12 at Mizuho
03/27/20 H.C. Wainwright
Evolus price target lowered to $16 from $31 at H.C. Wainwright
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
EOLS Evolus
$4.36 /

+0.22 (+5.31%)

Recommendations
Evolus price target lowered to $8 from $10 at Mizuho » 06:40
05/12/20
05/12
06:40
05/12/20
06:40
EOLS

Evolus

$4.36 /

+0.22 (+5.31%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan lowered the firm's price target on Evolus to $8 from $10 and keeps a Buy rating on the shares following the company's Q1 results. Jeuveau sales were impacted by the pandemic along with significantly greater than expected coupon redemptions that led to a 50% gross-to-net adjustment, Divan tells investors in a research note.

ShowHide Related Items >><<
EOLS Evolus
$4.36 /

+0.22 (+5.31%)

EOLS Evolus
$4.36 /

+0.22 (+5.31%)

04/17/20 Mizuho
Evolus price target lowered to $10 from $12 at Mizuho
03/27/20 H.C. Wainwright
Evolus price target lowered to $16 from $31 at H.C. Wainwright
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
03/04/20 Mizuho
Mizuho sees no change to Evolus story as focus on ITC case drives weakness
EOLS Evolus
$4.36 /

+0.22 (+5.31%)

Earnings
Evolus reports Q1 EPS (59c), consensus (59c) » 17:20
05/11/20
05/11
17:20
05/11/20
17:20
EOLS

Evolus

$4.36 /

+0.22 (+5.31%)

Reports Q1 revenue…

Reports Q1 revenue $10.5M, consensus $15.82M. "I am tremendously proud of the way our employees quickly responded to the challenges associated with the COVID-19 pandemic. We took decisive measures to help support our customers and strengthen our business with an increased reliance on our proprietary digital platform. Our efficient business model and innovative customer and consumer programs designed for the millennial segment are expected to drive continued share penetration," said David Moatazedi, president and CEO

ShowHide Related Items >><<
EOLS Evolus
$4.36 /

+0.22 (+5.31%)

04/17/20 Mizuho
Evolus price target lowered to $10 from $12 at Mizuho
03/27/20 H.C. Wainwright
Evolus price target lowered to $16 from $31 at H.C. Wainwright
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
03/04/20 Mizuho
Mizuho sees no change to Evolus story as focus on ITC case drives weakness
Over a month ago
Recommendations
Evolus price target lowered to $10 from $12 at Mizuho » 06:38
04/17/20
04/17
06:38
04/17/20
06:38
EOLS

Evolus

$4.31 /

-0.15 (-3.36%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan lowered the firm's price target on Evolus to $10 from $12 and keeps a Buy rating on the shares after the company adjusted its cost structure and commercialization strategy in the face of the COVID-19 pandemic.

ShowHide Related Items >><<
EOLS Evolus
$4.31 /

-0.15 (-3.36%)

03/27/20 H.C. Wainwright
Evolus price target lowered to $16 from $31 at H.C. Wainwright
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
03/04/20 Mizuho
Mizuho sees no change to Evolus story as focus on ITC case drives weakness
03/04/20 Stifel
Stifel remains supportive of Evolus' position in ITC case

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.